H.C. Wainwright analyst Mitchell Kapoor initiated coverage of Zura Bio with a Neutral rating and $5 price target. Zura is a clinical stage biotechnology company developing autoimmune disease therapeutics, the analyst tells investors in a research note. The firm says the data for lead asset tibulizumab appears mixed, with Phase 1 PK data not as clear as positive preclinical data.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZURA:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue